Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KHK | P50053 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30084906 | 1.00 | TRPV4 (0.57) | TRPV4CYP11B2CYP11B1KDM4EALDH1A1 | |
| SCHEMBL30084909 | 1.00 | TRPV4 (0.57) | TRPV4CYP11B2CYP11B1KDM4EALDH1A1 | |
| Fluoride SCHEMBL21646063 | 0.98 | TRPV4 (0.55) | TRPV4CYP11B2CYP11B1KDM4EALDH1A1 | |
| Methane SCHEMBL27650148 | 0.98 | TRPV4 (0.55) | TRPV4CYP11B2CYP11B1KDM4EALDH1A1 | |
| SCHEMBL7282150 | 0.84 | CYP11B2 (0.66) | TRPV4CYP11B2CYP11B1EGLN2 | |
| SCHEMBL30241198 | 0.82 | KDM4E (0.52) | TRPV4CYP11B2CYP11B1KDM4EALDH1A1 | |
| SCHEMBL145984 | 0.82 | KDM4E (0.52) | TRPV4CYP11B2CYP11B1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL2482616 | 0.80 | KDM4E (0.50) | TRPV4CYP11B2CYP11B1KDM4EALDH1A1 | |
| SCHEMBL10050188 | 0.79 | CYP19A1 (0.46) | TRPV4CYP11B2CYP11B1KDM4EALDH1A1 | |
| SCHEMBL981232 | 0.79 | CYP11B2 (0.65) | TRPV4CYP11B2CYP11B1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120117998-A | Preparation method of apatamide intermediate N-methyl-2-fluoro-4-aminobenzamide | 成都博腾药业有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-114276266-B | Preparation method of 4-amino-2-fluorobenzamide | 兰州康鹏威耳化工有限公司 | 2024-10-11 | — | — | CN | claimed |
| CN-115028642-B | Diaryl dihydrofuro [3,4-d ] pyrimidine HIV-1 reverse transcriptase inhibitor and preparation method and application thereof | 山东大学 | 2024-07-12 | — | — | CN | claimed |
| CN-116332789-A | Preparation method of 4-amino-2-fluorobenzamide | 上海康鹏科技股份有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-114276266-A | Preparation method of 4-amino-2-fluorobenzamide | 兰州康鹏威耳化工有限公司 | 2022-04-05 | — | — | CN | claimed |
| CN-108440559-B | Diaryl thienopyrimidine HIV-1 reverse transcriptase inhibitor and preparation method and application thereof | 山东大学 | 2020-06-16 | — | — | CN | claimed |
| CN-109678741-A | The preparation method of 4- amino -3- fluobenzoic acid | 金凯(辽宁)化工有限公司 | 2019-04-26 | — | — | CN | claimed |
| CN-108440559-A | Diaryl thienopyrimidines HIV-1 reverse transcriptase inhibitor and its preparation method and application | 山东大学 | 2018-08-24 | — | — | CN | claimed |
| JP-60163857-A | — | — | None | — | — | JP | disclosed |
| US-12612383-B2 | Polysubstituted pyrrolidine derivative, preparation method therefor and use thereof | SHANGHAI WENNAI THERAPEUTICS CO., LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-20260001886-A1 | ENPP1 INHIBITORS I | RE VENTURES I LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12503426-B2 | Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleoyl-LPI) and uses thereof | LIPOVEXA SRL (IT) | 2025-12-23 | — | — | US | disclosed |
| EP-4660186-A1 | ACID ADDITION SALT OF 4-AMINO-2-HALOBENZONITRILE COMPOUND AND METHOD FOR PRODUCING SAME | SUGAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2025-12-10 | — | — | EP | disclosed |
| US-4704227-A | DERIVATIVES OF 1,3-DIOXANE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1987-11-03 | — | — | US | disclosed |
| EP-0154840-A2 | Liquid crystal compounds | MERCK PATENT GmbH (DE) | 1985-09-18 | — | — | EP | disclosed |
| JP-S60163857-A | SYNTHESIS OF 2-FLUORO-4-THIOBENZONITRILE | HITACHI LTD | 1985-08-26 | — | — | JP | disclosed |
| US-4333940-A | Ring-fluorinated 4-(monosubstituted-amino) phenyl compounds in inhibiting atherosclerotic lesion development | AMERICAN CYANAMID COMPANY (US) | 1982-06-08 | — | — | US | disclosed |
| US-4243609-A | ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503426-B2 | Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleoyl-LPI) and uses thereof | GPR119, GLP1R, LPAR1 | TRPV4 1074/4885CYP11B2 3053/4885CYP11B1 2156/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | TRPV4 1449/4885CYP11B2 629/4885CYP11B1 796/4885 |
| US-20260001886-A1 | ENPP1 INHIBITORS I | ENPP1, ENPP2, ENPP3 | TRPV4 4401/4885CYP11B2 1971/4885CYP11B1 1208/4885 |
| US-12612383-B2 | Polysubstituted pyrrolidine derivative, preparation method therefor and use thereof | SCN8A, SCN11A, TRPV1 | TRPV4 17/4885CYP11B2 1139/4885CYP11B1 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.